
Tumor PDO 2.0
An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.
Models & products
Explore tumor PDOs, normal-tissue organoids and disease models. Find models and assays that fit your study.
Start from a common study combination or select up to three models.
Choosing PDO 1.0 or PDO 2.07 models shown
0 of 3 models selected for comparison

An ALI-based tumor model for studying treatment response alongside source-tissue architecture and immune cells retained from the sample.

Patient-derived breast tumor organoids for single-agent and combination studies, with PDO 2.0 / ALI considered when immune context is relevant.

Established from primary or metastatic colorectal tumors to compare drug response, tissue features and inter-sample differences.

Use conventional PDOs for HCC efficacy studies. Immunotherapy or anti-angiogenic programs can add PDO 2.0, vascular-marker profiling or a purpose-built co-culture.

Compare targeted and immune-related treatment conditions in renal cancer PDOs using apoptosis and immune-cell readouts.

Use conventional PDOs for pancreatic epithelial and drug-response studies, with ALI or custom co-culture added when stromal or immune context is important.

Case-specific model development, phenotype profiling and candidate-response studies for GIST, osteosarcoma and related tumors.
PRODUCT CATALOG

A starter kit for PDO 2.0 / ALI recovery and initial culture, with protocol guidance and technical support.

Core reagents for teams with ALI experience or preparing to establish a routine PDO 2.0 culture workflow.

Reagents and guidance for primary sample processing, organoid establishment, expansion and gentle passaging.

Configured around model type, cryopreservation scale and post-thaw QC for organoid storage, recovery and biobanking.

For TME-associated cell profiling by flow cytometry or immunofluorescence, with antibody panels matched to the model and assay platform.